Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.

M A PowellL BjørgeL WillmottZ NovákD BlackL GilbertS SharmaG ValabregaL M LandrumM Gropp-MeierA StuckeyI BoereM A GoldY SegevS E GillC GennigensA SebastianelliM S ShahinB PothuriB J MonkJ BuscemaR L ColemanB M SlomovitzK L RingT J HerzogM M BalasM GrimshawS StevensD W LaiC McCourtM R Mirza

Published in: Annals of oncology : official journal of the European Society for Medical Oncology (2024)

Dostarlimab in combination with carboplatin-paclitaxel demonstrated a statistically significant and clinically meaningful OS benefit in the overall population of patients with primary advanced or recurrent EC while demonstrating an acceptable safety profile.

Keyphrases

phase iii
endometrial cancer
open label
double blind
clinical trial
phase ii
placebo controlled
phase ii study
study protocol
chemotherapy induced
randomized controlled trial
radiation therapy
newly diagnosed